68426-83-5

Basic information

• Product Name: 5-Methoxy-1-methyl-1H-benzimidazole-2-methanol
• Synonyms: 1H-Benzimidazole-2-methanol,5-methoxy-1-methyl-(9CI);5-Methoxy-1-methyl-1H-benzimidazole-2-methanol;5-methoxy-N-methylbenzoimidazole-2-methanol;(5-methoxy-1-methyl-1H-benzimidazol-2-yl)methanol;(5-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)methanol;(5-methoxy-1-methyl-2-benzimidazolyl)methanol;(5-methoxy-1-methyl-benzimidazol-2-yl)methanol;(5-methoxy-1-methylbenzimidazol-2-yl)methanol
• CAS NO: 68426-83-5
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.21
• Product Categories: BENZIMIDAZOLE
• Mol File: 68426-83-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 193-195 ºC
• Boiling Point: 388.8°C at 760 mmHg
• Flash Point: 188.9°C
• Appearance: /
• Density: 1.24
• Vapor Pressure: 9.66E-07mmHg at 25°C
• Refractive Index: 1.595
• PKA: 13.66±0.10(Predicted)
• CAS DataBase Reference: 5-Methoxy-1-methyl-1H-benzimidazole-2-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxy-1-methyl-1H-benzimidazole-2-methanol(68426-83-5)
• EPA Substance Registry System: 5-Methoxy-1-methyl-1H-benzimidazole-2-methanol(68426-83-5)

Safety Data

• Hazardous Substances Data: 68426-83-5(Hazardous Substances Data)

Usage

General Description

5-Methoxy-1-methyl-1H-benzimidazole-2-methanol, also known as mebendazole, is a broad-spectrum anthelmintic drug that is used to treat various parasitic worm infections in humans. It works by inhibiting the formation of microtubules in the cells of the worms, leading to their immobilization and eventual death. Mebendazole is commonly prescribed for the treatment of helminth infections such as roundworm, whipworm, hookworm, and pinworm. It is available in different forms, including tablets, chewable tablets, and oral suspensions, and is usually taken as a single dose or in a series of doses over a few days. Despite its effectiveness, mebendazole may cause side effects such as abdominal pain, diarrhea, and nausea in some individuals. It is important for patients to follow their healthcare provider's instructions and dosage recommendations when taking mebendazole.

InChI:InChI=1/C10H12N2O2/c1-12-9-4-3-7(14-2)5-8(9)11-10(12)6-13/h3-5,13H,6H2,1-2H3

Upstream product

• 79-14-1 glycolic Acid 
• 3360-78-9 4-methoxy-N-methyl-1,2-phenylenediamine 
• 3360-79-0 N-methyl-4-methoxy-2-nitroaniline 
• 96-96-8 4-methoxy-2-nitroaniline 
• 20033-99-2 (5-methoxy-1H-benzimidazole-2-yl)-methanol 
• 74-88-4 methyl iodide 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 10394-39-5 5-methoxy-1-methyl-1H-benzo[d]imidazole 

Downstream Products

• 1357162-29-8 C₂₁H₂₀N₂O₄ 
• 1357162-32-3 C₂₀H₁₈N₂O₄ 
• 1357162-38-9 C₂₁H₂₀N₂O₄ 
• 1357162-41-4 C₂₀H₁₈N₂O₄ 
• 53004-19-6 5-methoxy-1-methyl-1H-1,3-benzodiazole-2-carbaldehyde 

Relevant articles and documents

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

Cytotoxicity of substituted benzimidazolyl curcumin mimics against multi-drug resistance cancer cell

-

Benzimidazole- and benzothiazole-quinones: Excellent substrates for NAD(P)H:quinone oxidoreductase 1

A series of benzimidazole- and benzothiazole-quinones has been synthesized. The ability of these heterocyclic quinones to act as substrates for recombinant human NAD(P)H:quinone oxidoreductase (NQO1), a two-electron reductase upregulated in tumour cells,